LTR Pharma (ASX:LTP) said its SPONTAN nasal spray product will be available through TerryWhite Chemmart's pharmacy network in Australia under its earlier distribution agreement with Symbion, according to a Tuesday Australian bourse filing.
TerryWhite Chemmart is a subsidiary of EBOS Group (ASX:EBO, NZE:EBO) alongside Symbion, the filing said.
LTR Pharma developed new commercial packaging for the SPONTAN intranasal spray, designed for pharmacy distribution and incorporating Therapeutic Goods Administration-compliant labeling, patient information materials, and pharmacy-standard barcodes.
The expanded pharmacy rollout will allow the firm to gather real-world data on SPONTAN usage to support its regulatory strategy and preparations for a full commercial launch following regulatory approval in Australia.
Its shares jumped over 38% in recent trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.